|
|
||||||||
under Steady-State Conditions1,2

* Department of Internal Medicine I, Molecular Tumor Biology and Tumor Immunology, University of Cologne, Cologne, Germany; and
Division for Theoretical Bioinformatics, German Cancer Research Center, Heidelberg, Germany
Based on studies in knockout mice, several inhibitory factors such as TGF
, IL-10, or CTLA-4 have been implicated as gate keepers of adaptive immune responses. Lack of these inhibitory molecules leads to massive inflammatory responses mainly mediated by activated T cells. In humans, the integration of these inhibitory signals for keeping T cells at a resting state is less well understood. To elucidate this regulatory network, we assessed early genome-wide transcriptional changes during serum deprivation in human mature CD4+ T cells. The most striking observation was a "TGF
loss signature" defined by down-regulation of many known TGF
target genes. Moreover, numerous novel TGF
target genes were identified that are under the suppressive control of TGF
. Expression of these genes was up-regulated once TGF
signaling was lost during serum deprivation and again suppressed upon TGF
reconstitution. Constitutive TGF
signaling was corroborated by demonstrating phosphorylated SMAD2/3 in resting human CD4+ T cells in situ, which were dephosphorylated during serum deprivation and rephosphorylated by minute amounts of TGF
. Loss of TGF
signaling was particularly important for T cell proliferation induced by low-level TCR and costimulatory signals. We suggest TGF
to be the most prominent factor actively keeping human CD4+ T cells at a resting state.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1 This work was mainly supported by the Alexander von Humboldt Foundation via Sofja-Kovalevskaja Awards (to J.L.S.). T.Z. was supported by the Frauke-Weiskam-Christel Ruranski Foundation and J.L.S. was supported by Grant TV89 from the Center for Molecular Medicine (Cologne, Germany). J.C. was supported by a fellowship from the Mildred Scheel Foundation from the Deutsche Krebshilfe. J.L.S. is a member of the Nationales Genomforschungsnetz (N1KR-S24T27).
2 S.C., T.Z., J.M.C., and J.L.S. designed the research. S.C., T.Z., J.M.C., I.B., A.P., M.B., and S.D. performed the research. S.C., T.Z., D.E., J.M.C., B.B., I.B., A.P., M.B., R.E., S.D., and J.L.S. analyzed the data. S.C., T.Z., D.E., B.B., R.E., and S.D. contributed reagents, material, and analysis tools. S.C., T.Z., D.E., and J.L.S. wrote the article.
3 S.C. and T.Z. contributed equally to this work.
4 Address correspondence and reprint requests to Dr. Joachim L. Schultze, Department of Internal Medicine I, Molecular Tumor Biology and Tumor Immunology, University of Cologne, Joseph-Stelzmann-Strasse 9, 50931 Cologne, Germany. E-mail address: Joachim.Schultze{at}uk-koeln.de
5 Abbreviations used in this paper: GO, gene ontology; ID, identification; aAPC, artificial APC; FC, fold change; PIGF, phosphatidylinositol glycan class F.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |